Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer : Is Rising Utilization Justified by Evidence?
| Errataetall: |
CommentOn: JAMA Oncol. 2021 Jan 1;7(1):52-58. - PMID 33237277 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
JAMA oncology - 7(2021), 1 vom: 01. Jan., Seite 59-60 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Daniel W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.03.2022 Date Revised 20.04.2022 published: Print CommentOn: JAMA Oncol. 2021 Jan 1;7(1):52-58. - PMID 33237277 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamaoncol.2020.6045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318039710 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318039710 | ||
| 003 | DE-627 | ||
| 005 | 20231225164526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaoncol.2020.6045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318039710 | ||
| 035 | |a (NLM)33237305 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Daniel W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer |b Is Rising Utilization Justified by Evidence? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2022 | ||
| 500 | |a Date Revised 20.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: JAMA Oncol. 2021 Jan 1;7(1):52-58. - PMID 33237277 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Nelson, Peter S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA oncology |d 2015 |g 7(2021), 1 vom: 01. Jan., Seite 59-60 |w (DE-627)NLM250070588 |x 2374-2445 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:59-60 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamaoncol.2020.6045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2021 |e 1 |b 01 |c 01 |h 59-60 | ||